Skip to main content

Pancreatic Cancer Treatment

Pancreatic Cancer Treatment Outcome Predicted By Genetic Test


A genetic tool developed in Japan allows clinicians to determine which patients may benefit the most from pancreatic cancer surgery to remove advanced tumors after first undergoing treatment to shrink the tumors.

The tumor marker gene (TMG) model involves combining the patients’ genetics with that of their tumor and was able to differentiate between patients who did well after surgery and those who did not. The research team, led by Nagoya University, now wants to further develop the TMG model score they created and to validate it for potential wider use.

“We found that the TMG model could more accurately identify which patients would really benefit from surgery. This could prevent some from undergoing unnecessary procedures and offer surgical opportunities to others who might have been overlooked,” said lead investigator Haruyoshi Tanaka from the Department of Surgery at Nagoya University Hospital in a press statement.

The Pancreatic Cancer Action Network predicts that 67,440 Americans will be diagnosed with pancreatic cancer this year and 51,980 people are predicted to die from the disease. It is one of the deadliest cancers with 5-year survival rates ranging from 8-13% depending on the type of pancreatic cancer, mainly because it is often diagnosed at a late stage.

“Some patients with unresectable disease at diagnosis may achieve a remarkable response by multimodal therapy and undergo subsequent surgery (so-called ‘conversion surgery’),” write Tanaka and co-researchers in the British Journal of Surgery.

“However, determining the appropriate indications for conversion surgery often presents a formidable challenge.” New biomarkers for pancreatic cancer include carbohydrate antigen 19-9 (CA19-9), DUPAN-2, and FUT2 and FUT3 and tests for these biomarkers in the blood can detect pancreatic cancer with a good degree of accuracy.

CA19-9 and DUPAN-2 are glycoproteins produced by pancreatic cancer cells and FUT2 and FUT3 are enzymes produced by the body that modify the actions of these glycoproteins but are also active when no cancer is present.

In this study, Tanaka and colleagues tested the biomarker status of advanced pancreatic cancer patients undergoing pancreatectomy surgery after first receiving treatment to shrink their tumors. They found genetic differences between patients linked to disease status and created the TMG model based on their findings.

Overall, people with a high score on their model had a worse outcome than those with a low score even after successful surgery. Although further testing is needed, the researchers believe the TMG model could help personalize surgical timing or avoid unnecessary surgery in high-risk patients. It could also help select which patients would most benefit from conversion surgery.

Pancreatic cancer, tumor markers, chemotherapy, immunotherapy, pancreatic adenocarcinoma, cancer diagnosis, cancer staging, pancreatic tumors, KRAS mutation, CA19-9, Whipple procedure, metastasis, oncogene, radiotherapy, pancreatic ductal carcinoma, early detection, genetic predisposition, cancer biomarkers, palliative care, clinical trials

#PancreaticCancer, #CancerResearch, #Oncology, #PancreaticAdenocarcinoma, #CancerAwareness, #KRAS, #TumorBiomarkers, #WhippleProcedure, #CancerDiagnosis, #MetastaticCancer, #Chemotherapy, #Radiotherapy, #CancerTreatment, #PalliativeCare, #EarlyDetection, #GeneticTesting, #ClinicalTrials, #Immunotherapy, #CancerSupport, #SurvivorStories

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetic Test

Genetic test eliminates progressive retinal atrophy in English shepherd dogs Researchers at the University of Cambridge recently published their findings in Genes after identifying the genetic mutation that is causing progressive retinal atrophy (PRA) in English shepherd dogs. PRA is a group of inherited diseases causing progressive degeneration of the light sensitive cells within the back of the eyes. When it comes to PRA in dogs, they are born with normal vision but by the age of 4-5 they go totally blind with no treatment. According to the release, by identifying the canines carrying this disease before they lose vision, this can be then used as a tool to guide breeding decisions to prevent the passing of the disease onto puppies.1 Historically, owners did not realize their dog had PRA until they were middle-aged, which means it could have been passed on to puppies if they had bred, making this a hard disease to control. “Once the dog’s eyesight starts to fail there’s no treatment ...
Post a Comment
Read more